Development and \textit{in Vitro-in Vivo} Evaluation of Controlled Release Matrix Tablets of Desvenlafaxine

Shashidhar Reddy Dodda\textsuperscript{1}, Prakash Rao Boggrapu\textsuperscript{2*}

\textsuperscript{1}Department of Pharmacology, Bioneeds Preclinical Services, Bangalore, India; \textsuperscript{2}Department of Pharmaceutics, Karnataka College of Pharmacy, Bangalore, India.

Email: *bpro_1111@rediffmail.com

Received October 14\textsuperscript{th}, 2011; revised November 20\textsuperscript{th}, 2011; accepted December 16\textsuperscript{th}, 2011

ABSTRACT

The objective of this investigation was to prepare extended release tablet containing matrix granules of Desvenlafaxine succinate monohydrate and to study its \textit{in vitro} release and \textit{in vivo} absorption. The design of dosage form was performed by choosing hydrophilic hydroxypropyl methyl cellulose (HPMC K100M), sodium carboxyl methyl cellulose (Blanose), microcrystalline cellulose (MCC) and lactose monohydrate polymers as matrix builders and polyvinyl pyrrolidone (Kollidon K30) as granulating polymers. Granules were prepared by composing drug with HPMC K100M, sodium CMC, MCC and lactose monohydrate by spray drying method. Optimized formulation of Desvenlafaxine succinate monohydrate was formed by using 20% HPMC K100M, 26.6% MCC, 6.6% of sodium CMC (Blanose), 13.3% of lactose monohydrate and 5% ratio of Kollidon K30 as binder. Tablets were compressed with free flowing optimized granules of uniform drug content. This extended the release period up to 24 h \textit{in vitro} study. Similarity factor and mean dissolution time were also reported to compare various dissolution profiles. The network formed by HPMC, MCC and Blanose had been coupled satisfactorily with the controlled resistance. Biopharmaceutical study of this optimized dosage form in rabbit model showed 24 h prolonged drug release \textit{in vivo}. A close correlation ($R^2 = 0.9833$) was established between the \textit{in vitro} release and the \textit{in vivo} absorption of drug. The results suggested that wet granulation with spray dried technique, is a suitable method to formulate sustained release Desvenlafaxine succinate monohydrate and it can Perform therapeutically better than conventional immediate release dosage form.

Keywords: Desvenlafaxine; Pharmacokinetics; ER Matrix Tablet; \textit{In Vitro} Kinetics; Depression

1. Introduction

Developing oral-sustained release formulations for highly water-soluble drugs with constant rate of release has become a challenge to the pharmaceutical technologists. Fast release drug generally causes toxicity if not formulated as extended release dosage form. Among various formulation approaches, in controlling the release of water-soluble drugs, the development of sustained release coated granules has a unique advantage of lessening the chance of dose dumping which is a major problem when highly water-soluble drug is formulated as matrix tablets. Most of the researchers have worked on matrix tablets and multilayered matrix tablets. In the present study, a sustained release dosage form of Desvenlafaxine (DV) has been developed that enables less frequent administering of drug [1-3]. Matrix granules of Desvenlafaxine were formed by appropriate combination of HPMC and sodium CMC, lactose monohydrate, MCC and Kollidon K30 was chosen to form the granules of extend duration of drug release.

Desvenlafaxine (o-desmethyl venlafaxine) is an active metabolite of Venlafaxine. Inhibits the neuronal uptake of nor epinephrine, serotonin and to a lesser extent dopamine but have no monoamine oxidase inhibitory activity and low affinity for brain muscaranic, cholinergic, histaminergic or alpha adrenergic receptors [4]. The solubility of Desvenlafaxine is highly dependent on pH; the significant pH dependency of solubility percents challenges the development of controlled release formulations of Desvenlafaxine for obtaining consistent dissolution profiles [5,6].

The objectives of this work were: 1) to evaluate the physical characters of prepared Tablets 2) to elucidate the effect of polymer composition and the release kinetics, 3) \textit{in vivo} study.

2. Materials and Methods

2.1. Materials

Desvenlafaxine succinictness monohydrate was obtained
Development and in Vitro-in Vivo Evaluation of Controlled Release Matrix Tablets of Desvenlafaxine

from Dr Reddy Ltd, Hyderabad, India. Hypermellose (Methocel K100M CR), Blanose (M31XFPH) were obtained as a gift sample from Colorcon AsiaPvt Ltd. Kollidon K30 and Microcrystalline cellulose (Avicell) was obtained from Rachem Pharma Pvt Ltd, Hyderabad. All other solvents, Reagents and Excipient were purchased from local vendors, India, and were of analytical grade.

2.2. Drug Excipient Interactions

The Possibility of Drug Excipient interaction was investigated by differential scanning calorimeter (DSC). The DSC Thermo gram of pure drug and Drug Excipient mixtures were recorded. The samples were separately sealed in aluminum cells and set in Metler TA 4000 Thermal analyzer.

2.3. Formulation

Different batches (DVF1, DVF2, DVF3, DVF4, DVF5, DVF6 and DVF7) were prepared according to the Table 1. Desvenlafaxine, Methocel K100M, Blanose and MCC and lactose monohydrate (passed through 40#) were mixed uniformly in polybag and granulated with aqueous solution of Kollidon K30 followed by spray drying at 60°C, he dried granules passed through #24 mesh and finally blend with Talc and magnesium state appropriate quantity and compressed with 9 mm round standard concave punches.

2.4. Physical Characterization of Tablets

Formulated tablets were subjected to different physical characterization studies. The weight variation was determined on 20 tablets using an electronic balance (Sartorius, Germany). Tablet hardness was determined for a minimum of six tablets using a Monsanto (Standard type, Cambridge, UK) tablet hardness tester. Ten tablets were taken and their thickness was recorded by a digital caliper (Mitutoyo, Kawasaki, Japan). Friability was calculated as the percentage weight loss of 20 tablets after Rotation using a Roche friabilator (Basel, Switzerland) for 4 min at 25 rpm.

2.5. Drug Content of Tablets

The drug content of the formulated tablets was estimated spectrophotometrically (Shimadzu UV-160A) after extraction in the methanol. Ten tablets were finely powdered; powder sample equivalent to 10 mg of Desvenlafaxine was accurately weighed and transferred to a 100 mL volumetric flask. Initially 50 mL of methanol was added to the volumetric flask and allowed to stand for 6 h with intermittent sonication to ensure complete solubility of the drug. Then the volume was made up with methanol and the mixture was centrifuged. The supernatant liquid was filtered through a 0.2-μm-membrane filter and Desvenlafaxine was analyzed spectrophotometrically at a wavelength of 240 nm.

2.6. In Vitro Dissolution Studies

The in vitro dissolution studies were performed by USP-30 type I dissolution apparatus at 100 rpm. The dissolution medium consisted of 0.9% Normal saline and the medium was maintained at 37°C ± 0.5°C. An aliquot (5 ml) was withdrawn at specific time intervals and replaced with the same volume of fresh medium at same temperature. The withdrawal sample was filtered through 0.45 μm filter paper. Next, its drug content was determined by UV-visible spectrophotometer (Shimadzu, Kyoto, Japan) at 240 nm. It was ascertained that none of the ingredients used in the matrix formulations interfered with the assay of drug (DV). The release studies were conducted in triplicate. Mean percent cumulative drug release was plotted against time of release.

2.7. Kinetics and Mechanism of Drug Release

Kinetics of drug release was determined by fitting data to

<table>
<thead>
<tr>
<th>Table 1. Composition of extended release matrix tablet of Desvenlafaxine succinate monohydrate.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ingredients (mg)</td>
</tr>
<tr>
<td>Desvenlafaxine succinate Monohydrate</td>
</tr>
<tr>
<td>Hypromellose (Methocel K15 MCR)</td>
</tr>
<tr>
<td>Blanose (M31XFPH)</td>
</tr>
<tr>
<td>Polyvinyl pyrrolidone (Kollidon K30)</td>
</tr>
<tr>
<td>Lactose monohydrate</td>
</tr>
<tr>
<td>MCC (Avicel)</td>
</tr>
<tr>
<td>Purified water</td>
</tr>
<tr>
<td>Talc</td>
</tr>
</tbody>
</table>
different equations such as zero order (M = kt), first order equation (M = lnM₀ + kt), Higuchi model (M = k√t) and Korsemeyer-Peppas equation (M = ktⁿ). A value of n = 0.5 indicates case I (Fickian) diffusion, 0.5 < n < 1 is for anomalous (non-Fickian) diffusion, n = 1 is for case II transport and n > 1 indicates supercase II transport. M is the amount of drug (%) released after time t; M₀ is the amount of drug released at zero time; k is the release rate constant and n is the exponent. Drug release following particular mechanism is judged by the linearity (R²) of plot [7].

2.8. Stability Studies

Stability studies were conducted on SR Tablets of select batch to assess their stability with respect to their physical appearance, drug content and release characteristics after storing at 25°C under 60% relative humidity (RH) and 40°C under 75% RH for 6 months [8].

2.9. Pharmacokinetic Evaluation

All animal studies were performed according to the Guidelines for the Care and Use of Laboratory Animals that was approved by the Committee of Ethics of Animal Experimentation of Bioneeds. Extended Release Tablets with 50 mg equivalent wt of Desvenlafaxine and 50mg equivalent wt of Desvenlafaxine suspension was administered to two groups (N = 3) orally via silicone rubber gastric intubation tube to male albino Rabbits with average weight of 2.5 kg which were housed individually in standard cage in a room with air, humidity and temperature control. The rabbit’s mouth was opened, and wooden rod was inserted between the jaws. A gastric tube was centrally placed to the hole (21.22). Tablets were set on the tip of a gastric intubation tube, and administered in to the stomach of rabbit [9]. After receiving the oral dose, 5 ml of water was administered to facilitate the accession of the tablets. Rabbits were fasted over night but had free access to water; 2 ml of blood samples were withdrawn from hepatic zed branule (G22, G24) placed in the marginal ear vein [10], at each of the pre determined times after administration: 0.25, 0.5, 1, 2, 4, 6, 8 and 24 hr. samples were transferred to 2 ml K2 EDTA coated tubes and centrifuged at 3000 rpm for 10 min. supernatant plasma was separated and transferred in to 96 well plate and stored at −20°C until Analyzed.

2.10. In Vivo Data Analysis

The maximum plasma concentration (Cₘₐₓ) and the time to reach the maximum concentration (tₘₐₓ) were directly obtained from the observed values. The area under the curve up to 24 h after administration (AUC) was calculated by the trapezoidal rule from the observed values.

3. Results and Discussion

In the present study, granules were prepared initially using various compositions (Table 1) of matrix forming polymers (HPMC, sodium CMC and MCC) with the help of granulating agent, PVP was used as Binder. Tablets were tested to check dissolution period up to 100% cumulative drug release. Prolonged release of drug was in the order of DVF3 < DVF2 < DVF1 < DVF6 < DVF7 < DVF5 tablets with code no DVF5 exhibited extended drug release up to 24 hr (Figure 1). Rate of drug release was significant (p < 0.005) when combination of HPMC and Blanose as a Matrix builder. Suitable combination of HPMC with sodium CMC and MCC gave the effect of both hydrophilic and hydrophobic polymer leading to controlled and prolonged release of drug (Figure 1, DVF5). It seems the pores formed by hydrophilic polymer (were filled by hydrophilic polymer making a well balanced matrix. Enhancement of permeability (HPMC) and retardation of permeation (sodium CMC, MCC) caused controlled and prolonged release of drug. Physical characteristics of these tablets were recorded and tabulated in Table 2.

The formulations after storing at 25°C/60% RH and 40°C/75% RH for 6 months showed no change in physical appearance and very slight change in dissolution pattern. The results of the stability studies indicated that the formulations could provide a minimum shelf life of 2 years.

Figure 1. In vitro release profile of Desvenlafaxine_ER tablets.
Development and in Vitro-in Vivo Evaluation of Controlled Release Matrix Tablets of Desvenlafaxine

Table 2. Drug release kinetic of Desvenlafaxine succinate formulations.

<table>
<thead>
<tr>
<th></th>
<th>DVF1</th>
<th>DVF2</th>
<th>DVF3</th>
<th>DVF4</th>
<th>DVF5</th>
<th>DVF6</th>
<th>DVF7</th>
</tr>
</thead>
<tbody>
<tr>
<td>Higuchi model (M = k t&lt;sup&gt;0.5&lt;/sup&gt;)</td>
<td>K</td>
<td>11.10 ± 0.84</td>
<td>10.54 ± 0.445</td>
<td>11.24 ± 0.713</td>
<td>11.09 ± 1.130</td>
<td>9.089 ± 1.20</td>
<td>10.85 ± 0.736</td>
</tr>
<tr>
<td></td>
<td>R&lt;sup&gt;2&lt;/sup&gt;</td>
<td>0.9403</td>
<td>0.9807</td>
<td>0.9575</td>
<td>0.8976</td>
<td>0.8392</td>
<td>0.9517</td>
</tr>
<tr>
<td>Peppas model (M = k t&lt;sup&gt;n&lt;/sup&gt;)</td>
<td>n</td>
<td>0.5190 ± 0.049</td>
<td>0.315 ± 0.028</td>
<td>0.411 ± 0.056</td>
<td>0.5794 ± 0.035</td>
<td>0.6017 ± 0.018</td>
<td>0.4769 ± 0.041</td>
</tr>
<tr>
<td></td>
<td>R&lt;sup&gt;2&lt;/sup&gt;</td>
<td>0.9244</td>
<td>0.9314</td>
<td>0.855</td>
<td>0.9672</td>
<td>0.9916</td>
<td>0.9373</td>
</tr>
<tr>
<td>First order (lnM = k t)</td>
<td>K</td>
<td>0.1398</td>
<td>0.1534</td>
<td>0.1323</td>
<td>0.1873</td>
<td>0.0941</td>
<td>0.1482</td>
</tr>
<tr>
<td></td>
<td>R&lt;sup&gt;2&lt;/sup&gt;</td>
<td>0.8745</td>
<td>0.8269</td>
<td>0.7549</td>
<td>0.9481</td>
<td>0.9961</td>
<td>0.9379</td>
</tr>
<tr>
<td>Zero order (M = k t)</td>
<td>K</td>
<td>3.968 ± 0.67</td>
<td>3.483 ± 0.730</td>
<td>3.632 ± 0.84</td>
<td>4.269 ± 0.56</td>
<td>3.797 ± 0.33</td>
<td>3.877 ± 0.64</td>
</tr>
<tr>
<td></td>
<td>R&lt;sup&gt;2&lt;/sup&gt;</td>
<td>0.7568</td>
<td>0.674</td>
<td>0.6295</td>
<td>0.8372</td>
<td>0.9224</td>
<td>0.7655</td>
</tr>
</tbody>
</table>

Next, the optimized tablets were intended for its in vivo test in rabbit. Plasma concentration and pharmacokinetic parameters after oral administration of formulated ER matrix tablet DVF5 and Desvenlafaxine suspension were summarized in Figure 2 and Table 3. No sustained blood level of DV was evident after oral administration of the immediate release formulation. No sustained blood level of DV was evident after oral administration of the immediate release formulation. The formulated matrix Tablet (DVF5) showed significantly lower C<sub>max</sub> than the immediate release formulation (P < 0.05) and required more time to reach C<sub>max</sub> (t<sub>max</sub> is 4 hr) as compared with immediate release formulation (t<sub>max</sub> is 0.5 hr). The AUC increased from 13190.25 hr*ng/ml to 35396.83 hr*ng/ml for ER tablets. Values of C<sub>max</sub> and t<sub>max</sub> clearly indicated that the drug release was sustained to about 24 h after oral administration in rabbits (n = 3). DVF5 Tablets maintained constant plasma concentration up to about 24 h. The maintenance of plasma concentration for longer duration after administration of new formulation (DVF5) indicates its smooth and extended in vivo absorption.

Results of the present study demonstrated that appropriate combination of both hydrophilic and hydrophobic polymers can be successfully employed for formulating extended release tablet of DV. By spray dried granules with PVP. Moreover extended release granules have a unique advantage of lessening chance of dose dumping which is a major problem when highly water-soluble drug is formulated as simple matrix tablets. The investigated sustained release matrix granules in tablet were capable of maintaining constant plasma level of DV up to 24 h in rabbits. Similar pharmacokinetic results can be predicted in humans also.

4. Conclusion

A new sustained release formulation of Desvenlafaxine succinate monohydrate has been developed and evaluated for its in vitro and in vivo drug release. Extended release granules in the form of matrix tablet were found to be an effective technique for a highly water-soluble drug Desvenlafaxine succinate monohydrate. Bioavailability studies should be done to assess the usefulness of this formulation in comparison with existing market products (Pristiq) of extended release Desvenlafaxine.

REFERENCES


